PT-141 (Bremelanotide) Research Guide: Melanocortin Receptor Agonism and Sexual Dysfunction Research
Shop Our Top Compounds
PT-141 (Bremelanotide) Research Guide: Melanocortin Receptor Agonism and Sexual Dysfunction Research
PT-141 (Bremelanotide) Research Guide: Melanocortin Receptor Agonism and Sexual Dysfunction Research
All compounds discussed in this article are for research purposes only. PT-141 (bremelanotide) as a research peptide is not for human consumption. The FDA-approved pharmaceutical product Vyleesi® is a separate prescription medication subject to regulatory oversight, with bremelanotide as its active ingredient.
Introduction: A Novel Central Nervous System Approach to Sexual Dysfunction Research
Among the hundreds of synthetic peptides studied in modern biomedical research, few have a discovery story as serendipitous—or a mechanism as scientifically distinctive—as PT-141 peptide. Also known by its International Nonproprietary Name bremelanotide, this cyclic heptapeptide is a synthetic peptide analog derived from alpha-melanocyte-stimulating hormone, specifically designed to target melanocortin receptors involved in sexual arousal. It emerged from melanocortin tanning research in the 1990s, when investigators at the University of Arizona unexpectedly observed potent pro-sexual effects in subjects receiving the melanocortin analog Melanotan II (Wessells et al., 1998).
What makes bremelanotide research uniquely significant is its mechanism of action. Unlike phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil and tadalafil—which act peripherally on vascular smooth muscle—the PT-141 peptide activates melanocortin receptors (primarily MC3R and MC4R) within the central nervous system. Unlike PDE5 inhibitors like Viagra, which increase blood flow to the genitals, PT-141 enhances sexual desire by activating central nervous system pathways, making it suitable for women whose low libido is not solely a physical issue. This centrally mediated pathway represents a fundamentally different pharmacological approach to sexual dysfunction, one rooted in the neurobiology of desire and arousal rather than hemodynamic changes.
The culmination of over two decades of bremelanotide research was the 2019 FDA approval of Vyleesi® (bremelanotide injection) for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 stands out as a groundbreaking treatment, introducing a brain-first approach to sexual dysfunction by targeting neural pathways and the melanocortin system, offering a novel mechanism compared to traditional therapies. This article provides a comprehensive review of the published scientific literature on PT-141 melanocortin receptor agonism, clinical trial data, safety profiles, and how this peptide compares mechanistically to other agents studied in sexual dysfunction research.
For researchers exploring the melanocortin system, PT-141 is available as a research compound through Iron Peak Peptides. Related melanocortin peptides, including Melanotan II, are also available for laboratory investigation.
The Melanocortin Receptor System: A Primer for Researchers
Overview of the MC1R–MC5R Receptor Family
To understand PT-141 peptide research, it is essential to understand the melanocortin receptor system it targets. The melanocortin system consists of five G-protein coupled receptors (GPCRs) designated MC1R through MC5R, their endogenous ligands—most notably alpha-melanocyte-stimulating hormone (α-MSH), which is a key natural ligand and the precursor for synthetic peptide analogs like PT-141—along with β-MSH, γ-MSH, and ACTH. The system also includes the endogenous antagonists agouti-related peptide (AgRP) and agouti signaling protein (ASIP), and accessory proteins known as melanocortin receptor accessory proteins (MRAPs) (Cai & Hruby, 2016).
Each melanocortin receptor subtype serves distinct physiological roles:
MC1R — Predominantly expressed in melanocytes of the skin. MC1R activation drives eumelanin synthesis, regulating skin and hair pigmentation. It also plays roles in immune modulation and inflammatory responses (Cai & Hruby, 2016).
MC2R — The ACTH receptor, expressed primarily in the adrenal cortex. MC2R mediates glucocorticoid synthesis and is essential for the hypothalamic-pituitary-adrenal (HPA) axis. Unlike the other melanocortin receptors, MC2R responds selectively to ACTH rather than α-MSH.
MC3R — Expressed in the hypothalamus, limbic system, and peripheral tissues. Research has demonstrated that MC3R plays important roles in energy homeostasis, feeding behavior, and cardiovascular regulation. MC3R is also expressed in the medial preoptic area (mPOA) of the hypothalamus, a region critical for sexual behavior.
MC4R — Widely expressed throughout the central nervous system, including the hypothalamus, cortex, brainstem, and spinal cord. MC4R is the receptor most extensively studied in the context of energy balance, appetite regulation, and sexual function. Research has shown MC4R activation in the hypothalamic mPOA triggers dopamine release, a key neurotransmitter in the excitatory pathway of sexual response (Clayton et al., 2021).
MC5R — Found in sebaceous glands, adrenal glands, and multiple other tissues. MC5R is implicated in exocrine gland function and immune regulation.
MC3R/MC4R Agonism: Why PT-141 Melanocortin Activity Matters
Bremelanotide research has established that PT-141 is a nonselective agonist at melanocortin receptors, but its effects on sexual function are primarily attributed to MC3R and MC4R activation within the CNS (Diamond et al., 2004). PT-141 works by targeting and activating specific receptors in the brain, namely MC3R and MC4R, which play a crucial role in regulating sexual function and desire. The MC4R agonist peptide mechanism is especially significant because MC4R is densely expressed in the medial preoptic area of the hypothalamus—a brain region that integrates hormonal, sensory, and neurotransmitter inputs to regulate sexual motivation and behavior.
Published preclinical studies have demonstrated that MC4R activation in the mPOA leads to increased release of dopamine, an excitatory neurotransmitter that promotes sexual desire. This mechanism was elucidated by Clayton et al. (2021), who proposed that bremelanotide activates presynaptic MC4Rs on neurons in the mPOA, leading to enhanced dopaminergic signaling. Simultaneously, this pathway may inhibit serotonergic and GABAergic inhibitory pathways that suppress sexual response.
This dual action—enhancing excitatory signaling while reducing inhibitory tone—represents a mechanistic paradigm distinct from all other pharmacological approaches to sexual dysfunction studied to date. Notably, PT-141 can enhance sexual arousal and desire even in the absence of visual sexual stimulation, underscoring its central mechanism of action. For a deeper exploration of melanocortin receptor terminology and other peptide science concepts, researchers can consult our glossary.
Discovery and Development: From Melanotan II to Bremelanotide
The Accidental Discovery of Pro-Sexual Effects
The story of PT-141 begins with Melanotan II (MT-II), a superpotent cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH), originally developed by researchers at the University of Arizona as a sunless tanning agent. Unlike hormonal treatments that act by altering hormone levels, Melanotan II exerts its effects independently of hormone levels, instead acting on central nervous system pathways. In 1998, Wessells and colleagues reported an unexpected finding: male subjects receiving subcutaneous MT-II in clinical studies experienced spontaneous penile erections as a side effect (Wessells et al., 1998). Notably, the erectile response induced by Melanotan II and similar centrally acting agents is mediated through central pathways, distinguishing it from traditional vasodilators that require sexual stimulation to provoke an erection.
This observation catalyzed a new line of investigation. Researchers recognized that Melanotan II activated multiple melanocortin receptor subtypes, producing diverse effects including skin pigmentation (via MC1R), appetite suppression (via MC4R), and the newly discovered pro-sexual activity (via MC3R/MC4R). However, MT-II’s broad receptor activity meant significant off-target effects, including nausea, facial flushing, and pronounced skin darkening.
Structural Optimization: The Creation of PT-141
To develop a more targeted compound for sexual dysfunction research, scientists at Palatin Technologies derived bremelanotide (PT-141) as a synthetic peptide analog—a carboxylated metabolite of Melanotan II—specifically designed to mimic or alter the activity of natural hormones by targeting melanocortin receptors involved in sexual arousal. This optimization led to bremelanotide being developed as the active ingredient in targeted sexual dysfunction therapies. The structural modification preserved the cyclic heptapeptide core responsible for melanocortin receptor activation while offering a more favorable pharmacological profile with reduced pigmentation effects compared to its parent compound (Molinoff et al., 2003).
The key structural feature of PT-141 peptide is its cyclic lactam bridge, which constrains the molecule into a bioactive conformation that enables efficient binding at MC3R and MC4R. With a molecular weight of approximately 1,025 Da and the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, bremelanotide retains melanocortin agonist activity while demonstrating greater selectivity for the CNS-mediated sexual function pathway.
For a comprehensive comparison of PT-141 and its parent compound, researchers may also refer to our Melanotan II Research Review.
Clinical Trial Evidence: Phase II and Phase III Data
Early Male Erectile Dysfunction Studies
The initial clinical evaluation of PT-141 peptide focused on male erectile dysfunction (ED), including research relevant to subgroups such as diabetic men who often have more challenging cases of ED. In a landmark Phase I/II study, Diamond et al. (2004) conducted a double-blind, placebo-controlled evaluation of intranasally administered PT-141 in healthy male subjects and in patients with mild-to-moderate ED. The study demonstrated that:
PT-141 produced a statistically significant erectile response compared to placebo at doses greater than 7 mg administered intranasally
The onset of the first erection occurred within approximately 30 minutes of administration
Mean C_max and AUC increased in a dose-dependent manner
Median T_max was 0.50 hours and mean half-life ranged from 1.85 to 2.09 hours
Flushing and nausea were the most common adverse events
Importantly, a subset of subjects achieved an erection sufficient for sexual intercourse
A critical finding from these early studies was that the erectogenic response was augmented by sexual stimulation, indicating that PT-141 worked in concert with natural arousal pathways rather than producing isolated physiological changes. This distinguished the MC4R agonist peptide from direct-acting vasodilator drugs such as PGE1, papaverine, and phentolamine, which are often used in patients who do not respond to oral PDE5 inhibitors (King et al., 2007).
Molinoff et al. (2003) further characterized PT-141 as an MC3R/MC4R agonist in preclinical models, demonstrating that systemic administration to rats activated neurons in the hypothalamus as shown by c-Fos immunoreactivity—neurons in the same region that project to the corpus cavernosum via the spinal cord.
In a subsequent study, Diamond et al. (2005) demonstrated that co-administration of low doses of intranasal PT-141 with sildenafil citrate produced an erectile response significantly greater than either compound alone, suggesting potentially complementary mechanisms between central melanocortinergic and peripheral vascular pathways. These findings are particularly relevant as research continues to explore emerging drugs for ED, aiming to improve outcomes for populations such as diabetic men and those with poor response to existing therapies.
Salvage of PDE5 Inhibitor Non-Responders
Research by Safarinejad and Hosseini (2008) evaluated intranasal bremelanotide in 342 men with erectile dysfunction who did not respond to sildenafil, representing an off-label use of bremelanotide. In this randomized, double-blind, placebo-controlled trial, the response rate was 33.5% in the bremelanotide group compared with 8.5% in the placebo group (p = 0.03). Subjects in the bremelanotide group also reported significantly greater intercourse satisfaction. These results indicate that bremelanotide produced significantly better results than placebo, demonstrating potential efficacy in a population refractory to the dominant pharmacological approach of PDE5 inhibition.
Phase III RECONNECT Studies in Female HSDD
The most extensive clinical evaluation of bremelanotide research came through the RECONNECT program—two parallel Phase III, randomized, double-blind, placebo-controlled trials (Study 301 and Study 302) enrolling approximately 1,247 premenopausal women with acquired, generalized hypoactive sexual desire disorder (Kingsberg et al., 2019).
Women who may benefit from PT-141 often describe feeling disconnected from their own body during intimate moments, experiencing a lack of sexual thoughts or fantasies, and distress about the gap between their desire and their partner’s expectations. These patient-reported outcomes highlight the neurological and psychological aspects of intimacy and desire restoration, and reinforce that therapy is focused on the individual’s well-being rather than fulfilling a partner’s expectations. Notably, clinical studies also reported improved quality of life and reduced emotional distress among participants.
Key findings from the integrated RECONNECT data included:
Primary endpoint: Bremelanotide (administered as 1.75 mg subcutaneous injection before anticipated sexual activity) produced statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain score compared to placebo, and increased the number of satisfying sexual events.
Co-primary endpoint: Significant reduction in distress as measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score
Secondary endpoints: Improvements across arousal, orgasm, overall FSFI scores, and increases in the frequency of sexual events and satisfying sexual events as measured outcomes
Duration: Efficacy was maintained across the 24-week double-blind treatment period
Simon et al. (2019) reported the 52-week open-label extension results, demonstrating sustained efficacy with a favorable long-term safety profile. Subjects who continued treatment maintained improvements in sexual desire and reductions in associated distress. The most commonly reported side effects of bremelanotide included flushing, nausea, vomiting, headache, diaphoresis, and lower back pain.
Prespecified subgroup analyses by Simon et al. (2022) demonstrated that bremelanotide’s effects were consistent across several subgroups, including by age, race, baseline severity, and hormonal contraceptive use, supporting the robustness of the clinical findings.
Early Female Sexual Arousal Research
Prior to the Phase III program, Diamond et al. (2006) conducted a pilot study in 18 premenopausal women with female sexual arousal disorder. Following a single intranasal dose of 20 mg bremelanotide, significantly more women reported moderate or high sexual desire compared to placebo (p = 0.0114). Among women who attempted sexual intercourse within 24 hours of treatment, significantly more were satisfied with their level of arousal following bremelanotide compared with placebo (p = 0.0256). While the study primarily relied on subjective reports, standardized measurement tools such as the International Index of Erectile Function (IIEF) or similar indices are commonly used in clinical trials to assess sexual function outcomes, though in this study, vaginal vasocongestion (measured by photoplethysmography) did not change significantly, reinforcing the central rather than peripheral mechanism of action.
Mechanism of Action: Central vs. Peripheral Pathways
How PT-141 Differs from PDE5 Inhibitors
The distinction between PT-141 melanocortin-mediated activity and PDE5 inhibitor mechanisms is fundamental to understanding sexual dysfunction peptide research. Comparative effectiveness studies are crucial in evaluating clinical outcomes between PT-141 and PDE5 inhibitors, helping determine which therapy may be more suitable for specific patient populations.
PDE5 Inhibitors (Sildenafil, Tadalafil, Vardenafil):
Oral medications that act peripherally on vascular smooth muscle
Inhibit phosphodiesterase type 5, preventing cGMP degradation
Enhance nitric oxide-mediated vasodilation in genital tissue
Require existing sexual stimulation and intact nitric oxide signaling
Primarily affect the hemodynamic component of erectile function by increasing blood flow
Do not directly influence sexual desire or central arousal pathways
PT-141 Peptide (Bremelanotide):
Acts centrally via MC3R/MC4R in the hypothalamus
Activates presynaptic melanocortin receptors in the mPOA
Increases dopamine release in brain regions governing sexual desire
May modulate serotonergic and GABAergic inhibitory pathways
Influences the motivational and desire components of sexual response
Functions through a mechanism independent of vascular effects
Notable for its rapid onset, PT-141 begins to enhance sexual arousal and desire soon after administration, making it a convenient alternative to oral medications for certain populations
This mechanistic divergence explains why bremelanotide research demonstrated efficacy in populations where PDE5 inhibitors were ineffective, including women with HSDD and men with ED non-responsive to sildenafil.
PT-141 vs. Melanotan II: Selectivity and Off-Target Effects
While both compounds are melanocortin receptor agonists derived from α-MSH, PT-141 and Melanotan II differ in important respects:
Feature | Melanotan II | PT-141 (Bremelanotide) |
|---|---|---|
Structure | Linear/cyclic hybrid | Cyclic heptapeptide (metabolite of MT-II) |
MC1R activity | High (skin pigmentation) | Lower relative activity |
MC3R/MC4R activity | High | High (preserved) |
Pigmentation effects | Pronounced | Minimal at recommended dosing |
Route studied | Subcutaneous | Intranasal (early), subcutaneous (approved) |
Regulatory status | Research compound | FDA-approved (as Vyleesi®) |
Research-grade PT-141 and Melanotan II are both available through Iron Peak Peptides for laboratory investigation.
Safety Profile and Adverse Events in Published Research
Clinical Trial Safety Data
The safety profile of bremelanotide has been comprehensively characterized across 43 completed clinical studies involving approximately 3,500 subjects in the clinical development program (Portman et al., 2022).
In the integrated Phase III RECONNECT data, the most common adverse events (bremelanotide vs. placebo) were:
Nausea: 40.0% vs. 1.3%
Flushing: 20.3% vs. 1.3%
Headache: 11.3% vs. 1.9%
Injection site reactions: 5.4% vs. 0.5%
These side effects—including nausea, flushing, and mild headaches—are generally mild and typically resolve on their own. Approximately 40% of users experience nausea with initial dosing, but this side effect usually decreases with subsequent use. Injection site reactions such as redness, swelling, or itching may occur, but these are generally mild and lessen with continued use of PT-141. Importantly, no significant adverse events were reported in the clinical trials, supporting the overall safety and tolerability of bremelanotide for research applications.
Nausea was the most frequently cited reason for treatment discontinuation. However, research has demonstrated that nausea tends to diminish with repeated dosing in many subjects.
Blood Pressure Considerations
Ambulatory blood pressure monitoring in the Phase III studies revealed small, transient, but statistically significant increases in blood pressure following bremelanotide administration. While these changes were not deemed clinically significant in the general study population, patients with uncontrolled hypertension were excluded from clinical trials due to safety concerns. The FDA label for Vyleesi® includes a recommendation for caution in patients with cardiovascular risk factors and advises that blood pressure should be well controlled during treatment (Portman et al., 2022).
Hyperpigmentation
Focal hyperpigmentation was rare when bremelanotide was dosed in accordance with label recommendations (no more than once every 24 hours). However, it occurred in more than one-third of subjects who received up to 16 consecutive daily doses in clinical protocols, reflecting the compound’s residual MC1R activity at high cumulative exposures (Portman et al., 2022).
Drug Interactions
Most drug–drug interactions evaluated in the clinical program showed an absence of significant interactions in most cases. Exceptions included interactions that lowered plasma concentrations of indomethacin and naltrexone when co-administered with bremelanotide.
Regulatory Status and Research Classification
The regulatory landscape for bremelanotide exists on two distinct levels. As a pharmaceutical product, Vyleesi® (bremelanotide injection, 1.75 mg) received FDA approval on June 21, 2019, for the treatment of acquired, generalized HSDD in premenopausal women. The recommended starting dose of PT-141 is typically 1.75 milligrams, taken at least 45 minutes before anticipated sexual activity. PT-141 is administered as a subcutaneous injection, usually in the abdomen or thigh, and should be given by a trained healthcare professional or with proper training for self-administration to ensure safety and proper technique. It is crucial to limit use to no more than one dose in a 24-hour period and no more than eight doses per month to ensure safety and effectiveness.
As a research compound, PT-141 peptide remains available for laboratory investigation under appropriate regulatory frameworks. Researchers studying melanocortin receptor biology, CNS pharmacology, or peptide structure-activity relationships continue to utilize PT-141 in preclinical models.
For a broader overview of how regulatory frameworks apply to research peptides, refer to our Peptide Regulation and FDA Status guide.
Peer-Reviewed Research Citations
The following published studies form the evidentiary basis for the research summarized in this article:
1. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. “Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.” Journal of Urology, 160(2), 389–393, 1998. DOI: 10.1016/S0022-5347(01)62916-X
2. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Annals of the New York Academy of Sciences, 994, 96–102, 2003. DOI: 10.1111/j.1749-6632.2003.tb03167.x
3. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. “Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.” International Journal of Impotence Research, 16(1), 51–59, 2004. DOI: 10.1038/sj.ijir.3901139
4. Diamond LE, Earle DC, Garcia WD, Spana C. “Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.” Urology, 65(4), 755–759, 2005. DOI: 10.1016/j.urology.2004.10.060
5. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. “An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.” Journal of Sexual Medicine, 3(4), 628–638, 2006. DOI: 10.1111/j.1743-6109.2006.00268.x
6. King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. “Melanocortin receptors, melanotropic peptides and penile erection.” Current Topics in Medicinal Chemistry, 7(11), 1098–1106, 2007. DOI: 10.2174/156802607780906681
7. Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. “Melanocortins in the treatment of male and female sexual dysfunction.” Current Topics in Medicinal Chemistry, 7(11), 1137–1144, 2007. DOI: 10.2174/156802607780906681
8. Safarinejad MR, Hosseini SY. “Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.” Journal of Urology, 179(3), 1066–1071, 2008. DOI: 10.1016/j.juro.2007.10.063
9. Cai M, Hruby VJ. “The melanocortin receptor system: a target for multiple degenerative diseases.” Current Protein and Peptide Science, 17(5), 488–496, 2016. DOI: 10.2174/1389203717666160226145330
10. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. “Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials.” Obstetrics & Gynecology, 134(5), 899–908, 2019. DOI: 10.1097/AOG.0000000000003500
11. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. “Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder.” Obstetrics & Gynecology, 134(5), 909–917, 2019. DOI: 10.1097/AOG.0000000000003514
12. Clayton AH, Lucas J, Jordan R, Spana C. “The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.” CNS Spectrums, 26(6), 629–636, 2021. DOI: 10.1017/S109285292100002X
13. Portman D, Jordan R, Lucas J, Kingsberg SA, Clayton AH. “Safety profile of bremelanotide across the clinical development program.” Journal of Women’s Health, 31(2), 171–182, 2022. DOI: 10.1089/jwh.2021.0191
14. Simon JA, Kingsberg SA, Portman D, Jordan R, Lucas J, Sadiq A, Krop J, Clayton AH. “Prespecified and integrated subgroup analyses from the RECONNECT phase 3 studies of bremelanotide.” Journal of Women’s Health, 31(3), 391–400, 2022. DOI: 10.1089/jwh.2021.0225
Frequently Asked Questions About PT-141 Peptide Research
What is PT-141 (bremelanotide) and how does it differ from other sexual dysfunction compounds?
PT-141 peptide, also known as bremelanotide, is a synthetic peptide—a lab-created cyclic heptapeptide—designed to mimic naturally occurring peptides and act as a melanocortin receptor agonist, primarily at MC3R and MC4R in the central nervous system. Unlike PDE5 inhibitors (sildenafil, tadalafil) that work peripherally on blood vessel smooth muscle, bremelanotide research has established that PT-141 acts centrally in the hypothalamus to modulate neurotransmitter pathways involved in sexual desire and arousal. This unique central mechanism provides a significant advantage over traditional treatments by addressing both psychological and physiological factors, leading to improved sexual performance and distinguishing PT-141 from all other compounds studied in sexual dysfunction research.
How was the pro-sexual effect of melanocortin agonists discovered?
The pro-sexual effects were discovered accidentally during clinical research on Melanotan II, a melanocortin analog developed as a sunless tanning agent. In 1998, researchers at the University of Arizona observed spontaneous penile erections in male subjects receiving subcutaneous MT-II injections. This serendipitous finding led to the development of PT-141 as a more targeted compound for sexual dysfunction research (Wessells et al., 1998).
What are the melanocortin receptors and which ones does PT-141 target?
The melanocortin receptor system consists of five G-protein coupled receptors (MC1R–MC5R) with diverse physiological functions ranging from pigmentation to energy homeostasis to adrenal steroid synthesis. PT-141 is a nonselective melanocortin receptor agonist, but its effects on sexual function are primarily attributed to activation of MC3R and MC4R in the hypothalamus, particularly in the medial preoptic area where MC4R activation leads to increased dopamine release (Clayton et al., 2021).
What clinical trial evidence supports bremelanotide research?
The most extensive evidence comes from the Phase III RECONNECT program—two randomized, double-blind, placebo-controlled trials enrolling approximately 1,247 premenopausal women with HSDD. These studies demonstrated statistically significant improvements in sexual desire scores and reductions in associated distress with bremelanotide 1.75 mg subcutaneous injection compared to placebo across a 24-week treatment period (Kingsberg et al., 2019). A 52-week open-label extension confirmed sustained efficacy and a favorable long-term safety profile (Simon et al., 2019).
What adverse events have been reported in bremelanotide clinical studies?
Across the clinical development program involving approximately 3,500 subjects, the most commonly reported adverse events were nausea (40.0% vs. 1.3% placebo), flushing (20.3% vs. 1.3%), headache (11.3% vs. 1.9%), and injection site reactions (5.4% vs. 0.5%). Small, transient blood pressure increases were observed during ambulatory monitoring. Focal hyperpigmentation was rare at recommended dosing frequency but more common with consecutive daily dosing (Portman et al., 2022).
How does PT-141 compare to Melanotan II in research contexts?
Both PT-141 and Melanotan II are melanocortin receptor agonists derived from α-MSH, but PT-141 is specifically a carboxylated metabolite of MT-II with reduced MC1R-mediated pigmentation activity. In published research, PT-141 has demonstrated a more favorable selectivity profile for the MC3R/MC4R-mediated sexual function pathway with fewer off-target effects related to skin darkening. Researchers can compare both compounds through our detailed Melanotan II Research Review.
What is the current regulatory status of PT-141?
Bremelanotide was approved by the FDA in June 2019 under the brand name Vyleesi® for the treatment of acquired, generalized HSDD in premenopausal women. As a pharmaceutical product, it is a prescription medication. As a research peptide, PT-141 remains available for laboratory investigation under appropriate regulatory frameworks. For current information on peptide regulatory classifications, see our Peptide Regulation and FDA Status guide.
Can PT-141 be used in combination with PDE5 inhibitors in research?
Published research by Diamond et al. (2005) demonstrated that co-administration of low-dose intranasal PT-141 with sildenafil produced an erectile response significantly greater than either compound alone in male subjects. This suggests potentially complementary mechanisms—central melanocortinergic activation combined with peripheral PDE5 inhibition—though further research is needed to fully characterize these interactions.
Conclusion: The Significance of PT-141 in Melanocortin Research
PT-141 peptide represents a paradigm-shifting approach in sexual dysfunction peptide research. By targeting melanocortin receptors MC3R and MC4R in the central nervous system, bremelanotide acts through neurotransmitter modulation in the hypothalamus—a mechanism entirely distinct from the peripheral vascular approach of PDE5 inhibitors. The extensive clinical trial data from the RECONNECT program, combined with earlier Phase I/II studies in both male and female populations, has established a robust evidence base supporting the role of melanocortin receptor agonism in sexual function.
For researchers investigating MC4R agonist peptides, melanocortin receptor biology, or CNS-mediated pathways in sexual function, PT-141 remains an important pharmacological tool. The published literature continues to expand, with ongoing investigations into melanocortin receptor signaling, potential combination approaches, and the broader implications of melanocortin system modulation.
PT-141’s unique mechanism addresses both neurological and psychological aspects of sexual health, making it a valuable compound for advancing sexual wellness and overall well-being. By supporting desire, arousal, and emotional satisfaction, PT-141 contributes to a holistic approach to sexual wellness that recognizes the interconnectedness of hormonal, neurological, and psychological factors. Ongoing research into PT-141 and related compounds is offering hope to individuals affected by sexual dysfunction, highlighting the potential for new treatments to improve quality of life.
Explore Iron Peak Peptides’ catalog of research-grade compounds, including PT-141, Melanotan II, and other peptides for laboratory investigation. Browse our full research peptide catalog to find the compounds your research requires.
Research Disclaimer
For research purposes only. The information presented in this article is intended for educational and informational purposes only and is based on published peer-reviewed scientific literature. This content does not constitute medical advice, diagnosis, or treatment recommendations.
PT-141 (bremelanotide) as discussed in this article refers to the research peptide compound. Research peptides are not for human consumption. The FDA-approved pharmaceutical product Vyleesi® is a separate prescription medication that should only be used under the supervision of a licensed healthcare provider.
Iron Peak Peptides supplies research-grade peptides exclusively for in vitro research, laboratory use, and scientific investigation. Researchers are responsible for ensuring compliance with all applicable federal, state, and local regulations governing the purchase and use of research compounds.
All clinical data and study results referenced in this article are drawn from published, peer-reviewed sources and are presented as scientific findings, not as evidence of therapeutic efficacy for any non-approved use. Individual research outcomes may vary.
Related Research
→ Buy PT-141 (Bremelanotide) for Research: Purity, Effects & Lab Testing
→ PT-141 (Bremelanotide): Complete Research Guide — Mechanisms, Clinical Evidence & Applications
Related Research
→ PT-141 (Bremelanotide): Complete Research Guide — Mechanisms, Clinical Evidence & Applications
→ PT-141 (Bremelanotide) Research Guide: Mechanism of Action, Clinical Studies & Scientific Review
🔬 Explore Research Peptides
- GHRP-2 10mg — $39.00
- Selank + Semax 10mg/10mg (20mg) — $89.00
- NAD+ 500mg — $69.99
- Prostamax 20mg — $65.00
